Great point Fouremm. As slide 16 represents, patients with ACS and diabetes have a 9.5% annual MACE rate and patients with ACS and CKD have a 31.6% annual MACE rate. Patients with ACS, CKD and diabetes may have an even higher annual MACE rate, but that combination is not shown on slide 16. Regardless, the about 250 patients (about 11% of total) in BETonMACE with ACS, CKD and diabetes will have a much greater risk of MACE compared to the about 2150 or so patient with ACS and diabetes but not CKD. As you suggest, Resverlogix and the Clinical Steering Committee likely took this balance into account in their estimations and this is a reasonable explanation for a projected annual MACE rate in all placebo patients (with and without CKD) being closer to 9.5% instead of the about 8% that was reported in EXAMINE.
BearDownAZÂ
